Cargando…

Role of ICAM1 in tumor immunity and prognosis of triple-negative breast cancer

BACKGROUND: Treating triple-negative breast cancer (TNBC) is a difficult landscape owing to its short survival times and high risk of metastasis and recurrence among patients. Although involved in tumor invasion and metastasis, the mechanism of action of intercellular adhesion molecule 1 (ICAM1), a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Qin, Xu, Jiawei, Xu, Yan, Sun, Shaokun, Chen, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475526/ https://www.ncbi.nlm.nih.gov/pubmed/37671167 http://dx.doi.org/10.3389/fimmu.2023.1176647

Ejemplares similares

Immune checkpoints expression patterns in early-stage triple-negative breast cancer predict prognosis and remodel the tumor immune microenvironment
por: Zhang, Jinguo, et al.
Publicado: (2023)

Tumor Mutation Burden and Immune Invasion Characteristics in Triple Negative Breast Cancer: Genome High-Throughput Data Analysis
por: Gao, Chundi, et al.
Publicado: (2021)

Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer
por: Qiu, Pengjun, et al.
Publicado: (2021)

Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer
por: Huang, Pengfei, et al.
Publicado: (2023)

Identification of necroptosis-related subtypes and prognosis model in triple negative breast cancer
por: Pu, Shengyu, et al.
Publicado: (2022)

High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer
por: Yeong, Joe, et al.
Publicado: (2018)

Evaluation of triple negative breast cancer with heterogeneous immune infiltration
por: Quintana, Ángela, et al.
Publicado: (2023)

Prognostic value of various immune cells and Immunoscore in triple-negative breast cancer
por: Ren, Xinyu, et al.
Publicado: (2023)

Immune landscape and risk prediction based on pyroptosis-related molecular subtypes in triple-negative breast cancer
por: Luo, Lixi, et al.
Publicado: (2022)

The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy
por: Li, Ruonan, et al.
Publicado: (2023)

ICAM-1 and ICAM-2 Are Differentially Expressed and Up-Regulated on Inflamed Pulmonary Epithelium, but Neither ICAM-2 nor LFA-1: ICAM-1 Are Required for Neutrophil Migration Into the Airways In Vivo
por: Chong, Deborah L. W., et al.
Publicado: (2021)

A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype
por: Chen, Zihao, et al.
Publicado: (2021)

Prognostic value and immune landscapes of TERT promoter methylation in triple negative breast cancer
por: Lin, Fei, et al.
Publicado: (2023)

Integrated profiling uncovers prognostic, immunological, and pharmacogenomic features of ferroptosis in triple-negative breast cancer
por: Fang, Kun, et al.
Publicado: (2022)

Effects of Hypoxia in Intestinal Tumors on Immune Cell Behavior in the Tumor Microenvironment
por: Zhang, Luping, et al.
Publicado: (2021)

PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis
por: Yu, Yinan, et al.
Publicado: (2023)

ICAMs are dispensable for influenza clearance and anti-viral humoral and cellular immunity
por: Kozlovski, Stav, et al.
Publicado: (2023)

CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
por: Zhou, Ru, et al.
Publicado: (2019)

Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer
por: Sha, Shengnan, et al.
Publicado: (2022)

ICAM-1 on Breast Cancer Cells Suppresses Lung Metastasis but Is Dispensable for Tumor Growth and Killing by Cytotoxic T Cells
por: Regev, Ofer, et al.
Publicado: (2022)

Sulindac sulfide as a non-immune suppressive γ-secretase modulator to target triple-negative breast cancer
por: Hossain, Fokhrul, et al.
Publicado: (2023)

Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer
por: Boissière-Michot, Florence, et al.
Publicado: (2022)

Facts and prospects of peptide in targeted therapy and immune regulation against triple-negative breast cancer
por: Huang, Yongxiu, et al.
Publicado: (2023)

Natural killer cell-related prognostic risk model predicts prognosis and treatment outcomes in triple-negative breast cancer
por: Liu, Zundong, et al.
Publicado: (2023)

Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
por: Zhou, Ru, et al.
Publicado: (2020)

Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer
por: Qiu, Jingdan, et al.
Publicado: (2016)

Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer
por: Zhao, Qing, et al.
Publicado: (2022)

ICAM1-Targeting Theranostic Nanoparticles for Magnetic Resonance Imaging and Therapy of Triple-Negative Breast Cancer
por: Chen, Jieying, et al.
Publicado: (2022)

VISTA Expression on Immune Cells Correlates With Favorable Prognosis in Patients With Triple-Negative Breast Cancer
por: Cao, Xi, et al.
Publicado: (2021)

The Obesity Paradox in Cancer, Tumor Immunology, and Immunotherapy: Potential Therapeutic Implications in Triple Negative Breast Cancer
por: Naik, Adviti, et al.
Publicado: (2019)

Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer
por: Zheng, Yiwen, et al.
Publicado: (2023)

Ferroptosis: the emerging player in remodeling triple-negative breast cancer
por: Li, Jie, et al.
Publicado: (2023)

HSPA8 Is a New Biomarker of Triple Negative Breast Cancer Related to Prognosis and Immune Infiltration
por: Ying, Bicheng, et al.
Publicado: (2022)

A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo
por: Guo, Peng, et al.
Publicado: (2023)

T-cadherin is associated with prognosis in triple-negative breast cancer
por: Kong, De-Di, et al.
Publicado: (2017)

Heterologous prime-boost cellular vaccination induces potent antitumor immunity against triple negative breast cancer
por: Niavarani, Seyedeh-Raheleh, et al.
Publicado: (2023)

CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancer
por: Cheng, Tianyi, et al.
Publicado: (2022)

Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer
por: Liubomirski, Yulia, et al.
Publicado: (2019)

A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors
por: Pérez-Pena, Javier, et al.
Publicado: (2019)

CD73 regulates zoledronate-induced lymphocyte infiltration in triple-negative breast cancer tumors and lung metastases
por: Petruk, Nataliia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1g0q7l8uhrqk8h3c279f1rak8f